Policy & Law

CMS Chief Answers to Congress, Provides Few Details on Reform’s Early Progress

1 Mins read

The first opportunity for the House to fire questions at Obama recess appointee (to CMS head) Donald Berwick, MD took place yesterday. Berwick took the time to affirm that the new healthcare law is already benefiting the elderly, would not raise premium costs in MA plans, and that House Republicans’ efforts to repeal the law were “unfortunate”. The all-powerful Ways and Means Cmte. walked away from Berwick’s testimony essentially unimpressed. The new CMS chief rebuffed Committee concerns over CMS actuarial data and testimony that forecasted higher costs and lower enrollment in MA plans as changes in government payments under the new healthcare law go into effect.

Berwick said that Medicare Advantage providers have been aggressive in advertising and enrolling new beneficiaries. […] ”This law means real improvements for Medicare beneficiaries, now and in the future,” Berwick said in his written testimony to the Ways and Means Committee. “That’s why the House vote to repeal this law was unfortunate.”

Seems an easy path for Berwick to take, as more Boomer healthcare consumers have begun to reach qualification for enrollment. Time will tell, however, if such mechanisms under reform (such as modifying the medical loss ratio in plans to cut administrative costs, the negative trajectory of HMO profits as a result of increases in MA and Medicare enrollment, and many anti-fraud initiatives) will back Berwick up in his assumptions.  

Related posts
Global HealthcarePolicy & Law

Do HMOs Deserve A Bad Reputation? The Truth Of Managed Healthcare

3 Mins read
Have you ever heard people say that HMO health insurance is no good? It’s no secret that HMOs have a bad reputation,…
Policy & Law

Top 4 Important Things To Understand About Insurance

2 Mins read
When it comes to Medicare, the enrollment process can be a little tricky. That’s why it’s important to understand the relevant health…
Health carePolicy & Law

Elmiron Controversy Highlights Need For Longterm Clinical Drug Testing

4 Mins read
Elmiron has recently been the subject of a number of lawsuits brought about over claims that the drug causes vision problems and may lead…